Marvel Biosciences Corp
XTSX:MRVL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Marvel Biosciences Corp
Depreciation & Amortization
Marvel Biosciences Corp
Depreciation & Amortization Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Depreciation & Amortization | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Marvel Biosciences Corp
XTSX:MRVL
|
Depreciation & Amortization
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abcellera Biologics Inc
NASDAQ:ABCL
|
Depreciation & Amortization
$22.2m
|
CAGR 3-Years
-7%
|
CAGR 5-Years
36%
|
CAGR 10-Years
N/A
|
|
|
B
|
Bright Minds Biosciences Inc
CNSX:DRUG
|
Depreciation & Amortization
CA$76.9k
|
CAGR 3-Years
134%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
Depreciation & Amortization
$19.4m
|
CAGR 3-Years
93%
|
CAGR 5-Years
70%
|
CAGR 10-Years
29%
|
|
|
Mind Medicine (MindMed) Inc
NASDAQ:MNMD
|
Depreciation & Amortization
$0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Eupraxia Pharmaceuticals Inc
TSX:EPRX
|
Depreciation & Amortization
CA$237.7k
|
CAGR 3-Years
8%
|
CAGR 5-Years
15%
|
CAGR 10-Years
N/A
|
|
Marvel Biosciences Corp
Glance View
Marvel Biosciences Corp. operates as a biotechnology company that utilizes a drug redevelopment approach to drug development. The company is headquartered in Calgary, Alberta. The company went IPO on 2019-02-28. The firm is focused on the discovery of new chemical entities that inhibit the A2a adenosine receptor. The firm has developed several new chemical entities, using synthetic chemical derivatives of known drugs, that inhibit the A2a adenosine receptor with application to neurological diseases, including depression and anxiety, Alzheimer’s, attention deficit hyperactivity disorder (ADHD), and the non-neurological conditions of cancer and non-alcoholic steatohepatitis. The firm is focused on the development of its lead molecule, MB-204 (Target 1b), which is in Phase I clinical trials. Its wholly owned subsidiary is Marvel Biotechnology Inc.
